Michael Seimetz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael Seimetz has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Pichl
Justus-Liebig University, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany
2 shared publications - Andreas Günther
Center for Interstitial and Rare Lung Diseases, Justus-Liebig-University, University of Giessen and Marburg Lung Center, Member of the German Center for Lung Research, Giessen, Germany
2 shared publications - Andreas Hecker
Department of General, Visceral, Thoracic and Transplant Surgery, University Hospital Giessen, Justus-Liebig-University Giessen, Rudolf-Buchheim-Strasse 6, 35392 Giessen, Germany
2 shared publications - Athanasios Fysikopoulos
Justus-Liebig University, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany
2 shared publications Baktybek Kojonazarov
Justus-Liebig University, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany
2 shared publications- Cheng-Yu Wu
Excellence Cluster Cardio-Pulmonary Institute (CPI), Institute for Lung Health (ILH), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus Liebig University (JLU), Giessen, Germany
2 shared publications
Latest Publications
- Open Access
- 26 June 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (7) , 648
Author Correction: NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 26 June 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (7) , 648
Open AccessAuthor Correction: NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 1 June 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (6) , 532-546
NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and death worldwide. Peroxynitrite, formed from nitric oxide, which is derived from inducible nitric oxide synthase, and superoxide, has been implicated in the development of emphysema, but the source of the superoxide was hitherto not characterized. Here, we identify the non-phagocytic NADPH oxidase organizer 1 (NOXO1) as the superoxide source and an essential driver of smoke-induced emphysema and pulmonary hypertension development in mice. NOXO1 is consistently upregulated in two models of lung emphysema, Cybb (also known as NADPH oxidase 2, Nox2)-knockout mice and wild-type mice with tobacco-smoke-induced emphysema, and in human COPD. Noxo1-knockout mice are protected against tobacco-smoke-induced pulmonary hypertension and emphysema. Quantification of superoxide, nitrotyrosine and multiple NOXO1-dependent signalling pathways confirm that peroxynitrite formation from nitric oxide and superoxide is a driver of lung emphysema. Our results suggest that NOXO1 may have potential as a therapeutic target in emphysema.
- 1 June 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (6) , 532-546
NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and death worldwide. Peroxynitrite, formed from nitric oxide, which is derived from inducible nitric oxide synthase, and superoxide, has been implicated in the development of emphysema, but the source of the superoxide was hitherto not characterized. Here, we identify the non-phagocytic NADPH oxidase organizer 1 (NOXO1) as the superoxide source and an essential driver of smoke-induced emphysema and pulmonary hypertension development in mice. NOXO1 is consistently upregulated in two models of lung emphysema, Cybb (also known as NADPH oxidase 2, Nox2)-knockout mice and wild-type mice with tobacco-smoke-induced emphysema, and in human COPD. Noxo1-knockout mice are protected against tobacco-smoke-induced pulmonary hypertension and emphysema. Quantification of superoxide, nitrotyrosine and multiple NOXO1-dependent signalling pathways confirm that peroxynitrite formation from nitric oxide and superoxide is a driver of lung emphysema. Our results suggest that NOXO1 may have potential as a therapeutic target in emphysema.